Reviewing Aeterna Zentaris Inc. (AEZS)’s and Magenta Therapeutics Inc. (NASDAQ:MGTA)’s results – The CoinGlobalist

Aeterna Zentaris Inc. (NASDAQ:AEZS) and Magenta Therapeutics Inc. (NASDAQ:MGTA) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

We can see in table 1 the earnings per share, top-line revenue and valuation of Aeterna Zentaris Inc. and Magenta Therapeutics Inc.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Liquidity

Aeterna Zentaris Inc.s Current Ratio and Quick Ratio are 2.3 and 2.2 respectively. The Current Ratio and Quick Ratio of its competitor Magenta Therapeutics Inc. are 17.2 and 17.2 respectively. Magenta Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Aeterna Zentaris Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Aeterna Zentaris Inc. and Magenta Therapeutics Inc.

On the other hand, Magenta Therapeutics Inc.s potential upside is 30.62% and its consensus target price is $18.

Insider & Institutional Ownership

The shares of both Aeterna Zentaris Inc. and Magenta Therapeutics Inc. are owned by institutional investors at 21.4% and 75.9% respectively. 0.6% are Aeterna Zentaris Inc.s share held by insiders. On the other hand, insiders held about 1.8% of Magenta Therapeutics Inc.s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Aeterna Zentaris Inc. has -70.92% weaker performance while Magenta Therapeutics Inc. has 133.16% stronger performance.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companys product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

More here:
Reviewing Aeterna Zentaris Inc. (AEZS)'s and Magenta Therapeutics Inc. (NASDAQ:MGTA)'s results - The CoinGlobalist